Safety and Immunogenicity against Ancestral, Delta and Omicron Virus Variants Following a Booster Dose of an Inactivated Whole-Virus COVID-19 Vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial

Christian  Taucher; Rajeka Lazarus; Hanna Dellago; Gabriele  Maurer; Petronela Weisova; Irena Čorbic Ramljak; Katrin  Dubischar; Anders  Lilja; Susanne  Eder-Lingelbach; Romana Hochreiter; Juan Carlos  Jaramillo; Helga  Junker; Michael Krammer; Petra  Pusic; Benedicte Querton; Julian  Larcher-Senn; Markus Hoffmann; Stefan  Pohlmann; Adam H R Finn

doi:10.1016/j.jinf.2023.06.022

Safety and Immunogenicity against Ancestral, Delta and Omicron Virus Variants Following a Booster Dose of an Inactivated Whole-Virus COVID-19 Vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial

Christian Taucher, Rajeka Lazarus, Hanna Dellago, Gabriele Maurer, Petronela Weisova, Irena Čorbic Ramljak, Katrin Dubischar, Anders Lilja, Susanne Eder-Lingelbach, Romana Hochreiter, Juan Carlos Jaramillo, Helga Junker, Michael Krammer, Petra Pusic, Benedicte Querton, Julian Larcher-Senn, Markus Hoffmann, Stefan Pohlmann, Adam H R Finn

Research output: Contribution to journal › Article (Academic Journal) › peer-review

10 Citations (Scopus)

Original language	English
Pages (from-to)	242-254
Number of pages	13
Journal	Journal of Infection
Volume	87
Issue number	3
DOIs	https://doi.org/10.1016/j.jinf.2023.06.022
Publication status	Published - 3 Jul 2023

Bibliographical note

Funding Information:
We thank the National Institute for Health and Care Research (NIHR) for recruitment support. We thank the EMA, MHRA, and Health Research Authority for their extraordinary efforts in rapidly reviewing submissions, for their attention to detail, and input into trial design. This report is independent research paid for by the Department of Health and Social Care. The views expressed in this publication are those of the authors and not necessarily those of the Department of Health and Social Care. The views expressed in this publication are those of the authors and not necessarily those of their employers or funders. We thank VisMederi srl Laboratories, Nexelis (a Q2 Solutions company), and Oxford Immunotec for immunogenicity analyses for this study. We Allucent and Assign Data Management and Biostatistics GmbH for excellent support with data management and data analysis. We thank all trial participants for their contribution, and the invaluable advice of the trial committees. Heinz Burgmann, Tom Wilkinson, Martin Sauer, Hermann Laferl, and Eva Poellabauer served as the independent members of the data and safety monitoring board. Finally, we thank Amy Kempf and Inga Nehlmeier for excellent technical support (pseudovirus neutralisation assays).

Publisher Copyright:
© 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jinf.2023.06.022

Handle.net

Persistent link

Cite this

Taucher, C., Lazarus, R., Dellago, H., Maurer, G., Weisova, P., Čorbic Ramljak, I., Dubischar, K., Lilja, A., Eder-Lingelbach, S., Hochreiter, R., Jaramillo, J. C., Junker, H., Krammer, M., Pusic, P., Querton, B., Larcher-Senn, J., Hoffmann, M., Pohlmann, S., & Finn, A. H. R. (2023). Safety and Immunogenicity against Ancestral, Delta and Omicron Virus Variants Following a Booster Dose of an Inactivated Whole-Virus COVID-19 Vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial. Journal of Infection, 87(3), 242-254. https://doi.org/10.1016/j.jinf.2023.06.022

Taucher, Christian ; Lazarus, Rajeka ; Dellago, Hanna et al. / Safety and Immunogenicity against Ancestral, Delta and Omicron Virus Variants Following a Booster Dose of an Inactivated Whole-Virus COVID-19 Vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial. In: Journal of Infection. 2023 ; Vol. 87, No. 3. pp. 242-254.

@article{6e68731b4bd54978b852b1b4d3452265,

title = "Safety and Immunogenicity against Ancestral, Delta and Omicron Virus Variants Following a Booster Dose of an Inactivated Whole-Virus COVID-19 Vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial",

author = "Christian Taucher and Rajeka Lazarus and Hanna Dellago and Gabriele Maurer and Petronela Weisova and \{{\v C}orbic Ramljak\}, Irena and Katrin Dubischar and Anders Lilja and Susanne Eder-Lingelbach and Romana Hochreiter and Jaramillo, \{Juan Carlos\} and Helga Junker and Michael Krammer and Petra Pusic and Benedicte Querton and Julian Larcher-Senn and Markus Hoffmann and Stefan Pohlmann and Finn, \{Adam H R\}",

note = "Funding Information: We thank the National Institute for Health and Care Research (NIHR) for recruitment support. We thank the EMA, MHRA, and Health Research Authority for their extraordinary efforts in rapidly reviewing submissions, for their attention to detail, and input into trial design. This report is independent research paid for by the Department of Health and Social Care. The views expressed in this publication are those of the authors and not necessarily those of the Department of Health and Social Care. The views expressed in this publication are those of the authors and not necessarily those of their employers or funders. We thank VisMederi srl Laboratories, Nexelis (a Q2 Solutions company), and Oxford Immunotec for immunogenicity analyses for this study. We Allucent and Assign Data Management and Biostatistics GmbH for excellent support with data management and data analysis. We thank all trial participants for their contribution, and the invaluable advice of the trial committees. Heinz Burgmann, Tom Wilkinson, Martin Sauer, Hermann Laferl, and Eva Poellabauer served as the independent members of the data and safety monitoring board. Finally, we thank Amy Kempf and Inga Nehlmeier for excellent technical support (pseudovirus neutralisation assays). Publisher Copyright: {\textcopyright} 2023",

year = "2023",

month = jul,

day = "3",

doi = "10.1016/j.jinf.2023.06.022",

language = "English",

volume = "87",

pages = "242--254",

journal = "Journal of Infection",

issn = "0163-4453",

publisher = "W.B. Saunders",

number = "3",

}

Taucher, C, Lazarus, R, Dellago, H, Maurer, G, Weisova, P, Čorbic Ramljak, I, Dubischar, K, Lilja, A, Eder-Lingelbach, S, Hochreiter, R, Jaramillo, JC, Junker, H, Krammer, M, Pusic, P, Querton, B, Larcher-Senn, J, Hoffmann, M, Pohlmann, S & Finn, AHR 2023, 'Safety and Immunogenicity against Ancestral, Delta and Omicron Virus Variants Following a Booster Dose of an Inactivated Whole-Virus COVID-19 Vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial', Journal of Infection, vol. 87, no. 3, pp. 242-254. https://doi.org/10.1016/j.jinf.2023.06.022

Safety and Immunogenicity against Ancestral, Delta and Omicron Virus Variants Following a Booster Dose of an Inactivated Whole-Virus COVID-19 Vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial. / Taucher, Christian ; Lazarus, Rajeka; Dellago, Hanna et al.
In: Journal of Infection, Vol. 87, No. 3, 03.07.2023, p. 242-254.

Research output: Contribution to journal › Article (Academic Journal) › peer-review

TY - JOUR

T1 - Safety and Immunogenicity against Ancestral, Delta and Omicron Virus Variants Following a Booster Dose of an Inactivated Whole-Virus COVID-19 Vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial

AU - Taucher, Christian

AU - Lazarus, Rajeka

AU - Dellago, Hanna

AU - Maurer, Gabriele

AU - Weisova, Petronela

AU - Čorbic Ramljak, Irena

AU - Dubischar, Katrin

AU - Lilja, Anders

AU - Eder-Lingelbach, Susanne

AU - Hochreiter, Romana

AU - Jaramillo, Juan Carlos

AU - Junker, Helga

AU - Krammer, Michael

AU - Pusic, Petra

AU - Querton, Benedicte

AU - Larcher-Senn, Julian

AU - Hoffmann, Markus

AU - Pohlmann, Stefan

AU - Finn, Adam H R

N1 - Funding Information: We thank the National Institute for Health and Care Research (NIHR) for recruitment support. We thank the EMA, MHRA, and Health Research Authority for their extraordinary efforts in rapidly reviewing submissions, for their attention to detail, and input into trial design. This report is independent research paid for by the Department of Health and Social Care. The views expressed in this publication are those of the authors and not necessarily those of the Department of Health and Social Care. The views expressed in this publication are those of the authors and not necessarily those of their employers or funders. We thank VisMederi srl Laboratories, Nexelis (a Q2 Solutions company), and Oxford Immunotec for immunogenicity analyses for this study. We Allucent and Assign Data Management and Biostatistics GmbH for excellent support with data management and data analysis. We thank all trial participants for their contribution, and the invaluable advice of the trial committees. Heinz Burgmann, Tom Wilkinson, Martin Sauer, Hermann Laferl, and Eva Poellabauer served as the independent members of the data and safety monitoring board. Finally, we thank Amy Kempf and Inga Nehlmeier for excellent technical support (pseudovirus neutralisation assays). Publisher Copyright: © 2023

PY - 2023/7/3

Y1 - 2023/7/3

U2 - 10.1016/j.jinf.2023.06.022

DO - 10.1016/j.jinf.2023.06.022

M3 - Article (Academic Journal)

C2 - 37406777

SN - 0163-4453

VL - 87

SP - 242

EP - 254

JO - Journal of Infection

JF - Journal of Infection

IS - 3

ER -

Taucher C, Lazarus R, Dellago H, Maurer G, Weisova P, Čorbic Ramljak I et al. Safety and Immunogenicity against Ancestral, Delta and Omicron Virus Variants Following a Booster Dose of an Inactivated Whole-Virus COVID-19 Vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial. Journal of Infection. 2023 Jul 3;87(3):242-254. doi: 10.1016/j.jinf.2023.06.022